Bellicum Pharmaceuticals (BLCM) has made some progress in their pipeline, company finances, and corporate agreements. Investors are still waiting for the company to close a partnership for Rivo-cel and the company's Houston manufacturing facility. However, management was able to close a licensing agreement with MD Anderson that has decided to exercise their option to use Bellicum's CaspaCIDe safety switch technology in their research. In return, Bellicum will receive an upfront payment of $5M, as well as milestones and royalties from products created with their technology. As a result, the share price popped over